Axsome Therapeutics (AXSM) Projected to Post Earnings on Monday

Key Points

• Q1 2026 earnings: Axsome is set to report before the market opens on Monday, May 4 (8:00 AM ET), with analysts forecasting ($0.80) EPS and $195.13M in revenue; the company beat the prior quarter's estimates and reported 65% year‑over‑year revenue growth.
• Significant insider sales: The COO and CEO sold large blocks of shares earlier this year, and insiders disposed of 100,288 shares worth about $17.14M over the last three months while insiders still own roughly 22.4% of the stock.
• Analyst optimism: Multiple brokerages have raised price targets (some up to $260) and the consensus rating is a "Moderate Buy" with an average price target of $218.06.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) is anticipated to release its Q1 2026 results before the market opens on Monday, May 4th. Analysts expect Axsome Therapeutics to post earnings of ($0.80) per share and revenue of $195.1310 million for the quarter. Interested persons may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Monday, May 4, 2026 at 8:00 AM ET.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last issued its quarterly earnings results on Monday, February 23rd. The company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.70) by $0.14. The company had revenue of $196.00 million for the quarter, compared to analysts' expectations of $191.33 million. Axsome Therapeutics had a negative return on equity of 232.61% and a negative net margin of 28.69%.The firm's revenue was up 65.0% on a year-over-year basis. On average, analysts expect Axsome Therapeutics to post $-1 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Axsome Therapeutics Price Performance

Shares of AXSM stock opened at $185.96 on Monday. The stock has a market cap of $9.51 billion, a price-to-earnings ratio of -50.40 and a beta of 0.48. The business's fifty day moving average is $170.37 and its 200 day moving average is $160.74. Axsome Therapeutics has a twelve month low of $96.09 and a twelve month high of $191.50. The company has a quick ratio of 1.48, a current ratio of 1.55 and a debt-to-equity ratio of 1.38.

Insiders Place Their Bets

In related news, COO Mark L. Jacobson sold 35,378 shares of the stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $161.88, for a total transaction of $5,726,990.64. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Herriot Tabuteau sold 32,410 shares of the stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $185.60, for a total value of $6,015,296.00. Following the sale, the chief executive officer directly owned 7,229 shares in the company, valued at $1,341,702.40. This trade represents a 81.76% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 100,288 shares of company stock valued at $17,138,187. 22.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Axsome Therapeutics

Several institutional investors have recently modified their holdings of AXSM. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Axsome Therapeutics by 4.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,923 shares of the company's stock valued at $2,557,000 after buying an additional 1,002 shares during the last quarter. Jones Financial Companies Lllp boosted its position in shares of Axsome Therapeutics by 2,407.9% during the first quarter. Jones Financial Companies Lllp now owns 7,624 shares of the company's stock valued at $889,000 after buying an additional 7,320 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Axsome Therapeutics by 38.7% during the first quarter. Goldman Sachs Group Inc. now owns 301,718 shares of the company's stock valued at $35,189,000 after buying an additional 84,151 shares during the last quarter. Caxton Associates LLP purchased a new stake in shares of Axsome Therapeutics during the first quarter valued at $307,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Axsome Therapeutics by 29.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 74,892 shares of the company's stock valued at $8,735,000 after buying an additional 17,250 shares during the last quarter. 81.49% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages recently weighed in on AXSM. Guggenheim upped their price target on Axsome Therapeutics from $220.00 to $245.00 and gave the stock a "buy" rating in a research note on Wednesday, March 25th. UBS Group upped their price target on Axsome Therapeutics from $251.00 to $259.00 and gave the stock a "buy" rating in a research note on Friday, April 10th. Leerink Partners upped their price target on Axsome Therapeutics from $150.00 to $205.00 and gave the stock an "outperform" rating in a research note on Wednesday, January 28th. Royal Bank Of Canada upped their price target on Axsome Therapeutics from $219.00 to $222.00 and gave the stock an "outperform" rating in a research note on Tuesday, February 24th. Finally, HC Wainwright upped their price target on Axsome Therapeutics from $200.00 to $260.00 and gave the stock a "buy" rating in a research note on Tuesday, January 20th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and two have given a Sell rating to the company. According to MarketBeat.com, Axsome Therapeutics has an average rating of "Moderate Buy" and an average price target of $218.06.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome's pipeline includes several late-stage and approved product candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.